Literature DB >> 14638345

Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study.

Lucio Gullo1, Marina Migliori, Massimo Falconi, Paolo Pederzoli, Rossella Bettini, Riccardo Casadei, Gianfranco Delle Fave, Vito D Corleto, Claudio Ceccarelli, Donatella Santini, Paola Tomassetti.   

Abstract

OBJECTIVES: Nonfunctioning pancreatic endocrine tumors (NFPTs) are rare neoplasms that have been the object of few studies that have involved only small numbers of patients. This study was carried out to obtain a comprehensive and up-to-date clinical picture of these tumors.
METHODS: A total of 184 patients with NFPT admitted to three Italian hospitals in the last 15 yr were studied. The diagnosis of NFPT was confirmed histologically using conventional and immunohistochemical techniques. Data were obtained from the medical charts or directly from the patients.
RESULTS: There were 85 men (46.2%) and 99 women (53.8%). The mean age at diagnosis was 55.2 yr (range 17-82 yr). The percentage of smokers and alcohol drinkers was similar to that in the general population. Seven patients (3.9%) had a family history of exocrine pancreatic carcinoma. In 120 cases (65.2%), the diagnosis was made after workup for pain or other symptoms, in the remaining 64 cases (34.8%), the tumor was discovered incidentally by ultrasound; in this group survival was significantly greater than it was for the symptomatic patients (p=0.0043). Survival was also found to be improved by tumor resection (p<0.0001), absence of metastases (p<0.0001), and small tumor size (< or =3 cm) (p<0.0007).
CONCLUSIONS: NFPTs were slightly more frequent in women and were diagnosed most often in middle-aged individuals. No risk factors other than a family history of exocrine pancreatic carcinoma were found. Tumor discovery while patients were still asymptomatic, tumor resection, absence of metastases, and tumor size < or =3 cm significantly prolonged survival.

Entities:  

Mesh:

Year:  2003        PMID: 14638345     DOI: 10.1111/j.1572-0241.2003.07704.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  37 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.

Authors:  Steven C Katz; Charan Donkor; Kristen Glasgow; Venu G Pillarisetty; Mithat Gönen; N Joseph Espat; David S Klimstra; Michael I D'Angelica; Peter J Allen; William Jarnagin; Ronald P Dematteo; Murray F Brennan; Laura H Tang
Journal:  HPB (Oxford)       Date:  2010-12       Impact factor: 3.647

3.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

4.  Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.

Authors:  David J Worhunsky; Geoffrey W Krampitz; Peter D Poullos; Brendan C Visser; Pamela L Kunz; George A Fisher; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

Review 5.  Pancreatic neuroendocrine tumors: overview of recent advances and diagnosis.

Authors:  Robert T Jensen
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

6.  Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series.

Authors:  Riccardo Casadei; Claudio Ricci; Raffaele Pezzilli; Davide Campana; Paola Tomassetti; Lucia Calculli; Donatella Santini; Nicola Antonacci; Francesco Minni
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 7.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 8.  Non-functional pancreatic neuroendocrine tumor as an incidentaloma--a case report and review of literature.

Authors:  Tarun Rustagi; Mridula Rai; Frank Bauer
Journal:  J Gastrointest Cancer       Date:  2013-09

9.  Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI.

Authors:  Giovanni Foti; Letizia Boninsegna; Massimo Falconi; Roberto Pozzi Mucelli
Journal:  Radiol Med       Date:  2013-07-25       Impact factor: 3.469

Review 10.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.